HanchorBio Inc.
TTWSE:7827149.50
TWD
-1.00
(-0.66%)
ISIN
KYG4277B1068
CUSIP
G4277B106
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Shi Gao Liu
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Taipei Taiwan
- IPO Date
- May 29, 2026
- Website
- hanchorbio.com
- Similar Companies
- Business
- HanchorBio Inc. is a clinical-stage biotechnology company that discovers, engineers, and develops next-generation multi-specific biologics and immunotherapies for the treatment of oncology and immune-mediated disorders. Founded in 2020 and headquartered in Taipei, Taiwan, the company maintains research, clinical development, and business operations across Taipei, Shanghai, China, and the San Francisco Bay Area, United States. HanchorBio operates primarily through its proprietary Fc-Based Designer Biologics (FBDB) platform, which combines artificial intelligence-guided molecular design with advanced protein engineering to construct multifunctional fusion proteins that simultaneously activate innate and adaptive immune responses to overcome tumor microenvironment defenses. The company's core product pipeline includes: HCB101, a clinical-stage SIRPalpha-Fc fusion protein targeting the CD47 immune checkpoint to disrupt cancer immune-evasion signaling in advanced solid tumors and hematologic malignancies; HCB301, a clinical-stage tri-functional fusion protein engineered to inhibit transforming growth factor-beta (TGF-beta) and overcome tumor immune exclusion; HCB303, a preclinical multi-specific immuno-oncology fusion candidate; and HCB206, a targeted designer biologic developed for autoimmune indications, including systemic lupus erythematosus (SLE). Recent strategic developments include the company's public listing on the Taiwan Stock Exchange Taiwan Innovation Board under ticker 7827; a comprehensive biologics development and GMP manufacturing agreement with WuXi Biologics to scale global clinical supply; a regional development and commercialization licensing alliance with Shanghai Henlius Biotech for lead candidate HCB101; a translational collaboration with the Taiwan Cancer Moonshot Program and National Taiwan University focused on multi-omics biomarker identification; an artificial intelligence clinical trial simulation partnership with InSilicoTrials; and receipt of U.S. Food and Drug Administration authorization for an individual-patient Expanded Access protocol for HCB101 following Phase 1 clinical studies.